Search Within

Pamela R Drullinsky

Formats
  1. Meeting Abstract (58)
  2. Journal Article (31)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Breast Medicine Service (91)
  2. Department of Medicine (91)
  3. Solid Tumor Oncology Division (91)
  4. Survivorship Research (69)
  5. Epidemiology and Biostatistics (47)
  6. Population Sciences Research Program (46)

More Groups

People
  1. Andrew Zelenetz (35)
  2. Matthew Matasar (32)
  3. Anita Kumar (31)
  4. David Straus (31)
  5. Paul Hamlin (31)
  6. Alison Moskowitz (26)

More People

Years
  1. 2024 (4)
  2. 2023 (1)
  3. 2022 (9)
  4. 2021 (10)
  5. 2020 (8)
  6. 2019 (4)

More Years

Publications
  1. Journal of Clinical Oncology (20)
  2. Blood (17)
  3. Breast Cancer Research and Treatment (10)
  4. Cancer Research (9)
  5. Hematological Oncology (6)
  6. Clinical Cancer Research (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. American Society of Hematology (17)
  3. American Association for Cancer Research (13)
  4. Springer (10)
  5. Elsevier Inc. (8)
  6. Wiley Blackwell (6)

More Publishers

Results (91)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of ganetespib: Efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D'Andrea, G.; Haque, S.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A novel capecitabine schedule (7 on—7 off) is feasible with lapatinib for patients with HER2-positive metastatic breast cancer refractory to trastuzumab
    Meeting Abstract

    Gajria, D.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Drullinsky, P.; D'Andrea, G.; Lake, D.; Norton, L.; Hudis, C.; more...
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Changes in bone mineral density (BMD) of postmenopausal women who are not receiving adjuvant endocrine therapy for breast cancer (BCA)
    Meeting Abstract

    Van Poznak, C.; Morris, P. G.; D'Andrea, G.; Schott, A.; Griggs, J.; Fornier, M.; Smerage, J.; Henry, L.; Collins, T.; Hurria, A.; more...
    Bone (2010)

    Fulltext@MSK | Save
  • Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer
    Journal Article

    Drullinsky, P.; Sugarman, S. M.; Fornier, M. N.; D'Andrea, G.; Gilewski, T.; Lake, D.; Traina, T.; Wasserheit-Lieblich, C.; Sklarin, N.; Atieh-Graham, D.; more...
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer
    Meeting Abstract

    Drullinsky, P.; Fornier, M. N.; Sugarman, S.; D'Andrea, G.; Troso-Sandoval, T.; Seidman, A. D.; Yuan, J.; Patil, S.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma
    Journal Article

    Sugarman, S.; Wasserheit, C.; Hodgman, E.; Coglianese, M.; D'alessandro, A.; Fornier, M.; Troso-Sandoval, T.; D'Andrea, G.; Drullinsky, P.; Lake, D.; more...
    Breast Cancer Research and Treatment (2009)

    Fulltext@MSK | Save
  • Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT)
    Meeting Abstract

    Conlin, A. K.; D'Andrea, G.; Hudis, C. A.; Robson, M. E.; Drullinsky, P.; Theodoulou, M.; Lis, E.; Kang, T. Y.; Peereboom, D. M.; Seidman, A. D.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BC): First safety results
    Meeting Abstract

    Dang, C.; Lin, N.; Lake, D.; Theodoulou, M.; Drullinsky, P.; Gorsky, M.; Chen, C.; Norton, L.; Winer, E.; Hudis, C.
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save